Abstract
The purpose of this paper is to share some recent observations on the pharmaceuticaluses and properties of Captisol® or SBE7M-β-CD in controlled porosity osmotic pump tablets (CP-OPT) and the underlying mechanism/sthat lead to apparent zero-order drug release pattern. It would have been simple toattribute the apparent zero-order release mechanism/s of poorly water-soluble drugsfrom CP-OPTs and pellets utilizing Captisol®as both a solubilizing andosmotic agent, to purely osmotic and diffusional components. However, the mechanismmay be more related to a counterbalancing of physical properties as the concentration of Captisol®changes within the matrix. Specifically, the initial concentration of Captisol®within a core is 0.3–0.4M. When this drops to lower values an osmotic pressure drop occurs across the membrane. Therefore, drug release should not follow apparent zero-order kinetics if all the drug is solubilized. However, as the viscosity within the tablet also drops, the apparent diffusion coefficient of both Captisol® and drug increases. Therefore, it appears that there is an initial resistance (hydraulic pressure) to fluid flow from the tablet through the rate-limiting microporous membrane. This resistance decreases so that even as osmotic pressure and concentration differences drop with time, counterbalancing faster release occurs. Osmotic driving force appears to be the most important initial driving force but a diffusional component becomes more significant with time.
Similar content being viewed by others
REFERENCES
G.M. Zentner, G.S. Rork, and K.J. Himmelstein: J. Cont. Rel. 1, 269–282 (1985).
G.M. Zentner, G.S. Rork and K.J. Himmelstein: J. Cont. Rel. 2, 217–229 (1985).
G.M. Zentner, G.S. Rork, K.J. Himmelstein (Merck & Co., Inc.): U.S. Patent 4,968,507 (1990).
F. Theeuwes: J. Pharm. Sci. 64, 1987–1991 (1975).
K. Okimoto, M. Miyake, N. Ohinishi, R.A. Rajewski, V.J. Stella, T. Irie, and K. Uekama: Pharm. Res. 15, 1562–1568 (1998).
K. Okimoto, A. Ohike, R. Ibuki, O. Aoki, N. Ohinishi, T. Irie, K. Uekama, R.A. Rajewski, and V.J. Stella: Pharm. Res. 16, 549–554 (1999).
K. Okimoto, R.A. Rajewski and V.J. Stella: J. Cont. Rel. 58, 29-38 (1999).
K. Okimoto, A. Ohike, R. Ibuki, O. Aoki, N. Ohinishi, R.A. Rajewski, V.J. Stella, T. Irie, and K. Uekama: J. Cont. Rel. 60, 311–319 (1999).
E.A. Zannou, W.H. Streng, and V.J. Stella: Pharm. Res. 18, 1226–1231 (2001).
S. Proniuk and J. Blanchard: J. Pharm. Sci. 90, 1086–1090 (2001).
R.A. Rajewski, G. Traiger, J. Bresnahan, V.J. Stella, and D. O. Thompson: J. Pharm. Sci. 84, 927–932 (1995).
K. Shiotani, K. Uehata, T. Irie, K. Uekama, D.O. Thompson, and V.J. Stella: Pharm. Res. 12, 78–84 (1995).
V.J. Stella and R.A. Rajewski: Pharm. Res. 14, 556–567 (1997).
D.O. Thompson: Crit. Rev. Ther. Drug Carrier Syst. 14, 1–104 (1997).
E.A. Zannou, A Mechanistic Study of Drug Release from Cyclodextrin-Based Controlled Porosity Osmotic Pump Tablets, Ph.D. Dissertation to the University of Kansas, May, 2000.
A.G. Ozturk, S.S. Ozturk, B.O. Palsson, T.A. Wheatley, and J.B. Dressman: J. Cont. Rel. 14, 203–213 (1990).
Rights and permissions
About this article
Cite this article
Stella, V.J., Rao, V.M. & Zannou, E.A. The Pharmaceutical Use of Captisol®: Some Surprising Observations. Journal of Inclusion Phenomena 44, 29–33 (2002). https://doi.org/10.1023/A:1023068414272
Issue Date:
DOI: https://doi.org/10.1023/A:1023068414272